查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1766097

全球動物疫苗市場：2032 年預測 - 按類型、動物、疾病、技術、最終用戶和地區進行分析

Veterinary Vaccine Market Forecasts to 2032 - Global Analysis By Type, Animal, Disease, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球動物疫苗市場預計在 2025 年達到 129.8 億美元，預計到 2032 年將達到 219.7 億美元，預測期內的複合年成長率為 7.8%。

獸用疫苗是生物製藥，透過刺激動物免疫系統來保護動物免受某些感染疾病。疫苗含有源自病毒、細菌或寄生蟲等病原體的抗原，這些抗原能夠引發免疫反應，但本身並不會導致疾病。獸用疫苗是預防疾病爆發、改善動物福利和提高食品安全的重要工具。它們廣泛用於家養寵物和牲畜，以減少通用感染疾病的傳播，提高生產力，並減少動物健康管理中對抗生素的依賴。

根據中國國家統計局預測，2023年中國豬肉產量將達5,794萬噸，比上年增加5%。

通用和感染疾病感染疾病的盛行率增加

隨著動物傳播給人類的疾病種類不斷增加，採取預防措施保護公眾健康的需求也日益增加。為了保護牲畜，避免疾病爆發造成的經濟損失，畜牧生產者投入大量資金購買疫苗。為了遏止疾病傳播，政府和衛生機構大力推廣疫苗接種計畫。新型疾病病毒株的出現進一步加劇了人們對現代先進疫苗的需求。這種緊迫感和日益增強的意識正在推動獸用疫苗產業的創新和發展。

高成本和嚴格的監管核准

開發創新疫苗需要在最尖端科技和專業知識方面投入大量資金。這些成本往往會延遲產品的上市，並限制規模較小的競爭對手的進入。嚴格的監管核准需要進行大量的安全性和有效性測試，這增加了複雜性。漫長的上市時間和冗長而昂貴的核准流程扼殺了創新。所有這些變數共同限制了全球新型動物疫苗的供應和發展。

疫苗技術和個人化醫療的進展

基於載體的疫苗接種、基於mRNA的疫苗以及重組DNA技術等技術創新，改善了免疫反應並減少了副作用。這些技術還能快速應對新出現的通用感染疾病。個人化動物照護正在推動基於動物物種、品種和健康狀況的專門疫苗接種方案的需求。透過這些有針對性的策略，動物生產力和疾病預防得到了提升。總體而言，這些動態正在顯著推動獸用疫苗市場的成長和相關性。

低收入地區的疫苗抗藥性和有限的低溫運輸基礎設施

文化信念、錯誤訊息以及對疫苗有效性的懷疑都是造成這種抵制的原因之一。此外，低溫運輸基礎設施不足影響了疫苗的儲存和運輸，從而降低了疫苗的有效性。冷藏設施不足和電力供應不穩定進一步加劇了這個問題。這些問題導致疾病爆發和疫苗接種率低。因此，這些地區獸用疫苗市場的擴張和有效性持續受到限制。

COVID-19的影響

新冠疫情對獸用疫苗市場的影響不大。儘管疫情期間供應鏈中斷和獸醫就診量減少暫時阻礙了疫苗的分銷和銷售，但隨著寵物飼養量的增加和動物健康意識的增強，該行業已逐漸復甦。各國政府和相關人員更加重視動物疾病預防，以避免通用感染疾病的爆發，從而推動了疫苗需求。此外，疫情推動的生物技術和診斷工具的進步加速了獸用疫苗開發的創新，支持了市場復甦和長期成長。

預測期內，重組疫苗市場預計將成為最大的市場

由於更安全的疫苗接種解決方案，重組疫苗領域預計將在預測期內佔據最大的市場佔有率。這些疫苗降低了病原體復發的風險，並提高了動物安全性和疫苗穩定性。它們能夠快速研發針對新興疾病的疫苗，並支持及時應對疫情。它們能夠高效誘導強烈的免疫反應，從而減少給藥次數並提高依從性。此外，先進生物技術在動物保健領域的日益普及也推動了全球對重組疫苗的需求。

預計預測期內居家醫療領域將以最高的複合年成長率成長。

在預測期內，居家醫療領域預計將實現最高成長率，因為它能夠方便及時地接種疫苗，尤其是針對伴侶動物。這減少了頻繁就診獸醫的需求，使預防性醫療保健更容易獲得，並減輕寵物及其飼主的壓力。寵物擁有量的增加和人們對動物健康的認知不斷提高，推動了家庭疫苗及相關服務的需求。使用者友善的疫苗注射系統等技術進步正在進一步促進家庭疫苗接種。這種轉變將提高疫苗接種依從性，從而促進整體市場的成長。

佔比最大的地區：

在預測期內，亞太地區預計將佔據最大的市場佔有率，這得益於牲畜存欄量的增加、人們對動物健康的認知不斷提高以及政府的支持性舉措。中國、印度和澳洲等國家對口蹄疫、豬瘟和禽流感疫苗的需求正在增加。肉類和乳製品產業的擴張以及獸醫基礎設施的建設正在進一步推動市場發展。然而，監管壁壘和農村地區低溫運輸物流受限等挑戰依然存在。

複合年成長率最高的地區：

預計北美地區在預測期內的複合年成長率最高。這得益於其先進的動物保健系統、強大的研發投入以及對伴侶動物健康的高度重視。美國和加拿大在創新和疫苗採用方面處於領先地位，這得益於DNA和重組疫苗等技術的廣泛應用。嚴格的法律規範確保了疫苗質量，但同時也為新產品的進入帶來了挑戰。與亞太地區不同，寵物保險和獸醫診所的可及性反映了成熟的技術密集型模式，對市場動態產生了重大影響。

免費客製化服務

本報告的所有訂閱者均可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他公司（最多 3 家）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 市場機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

第5章。全球動物疫苗市場（按類型）

  • 去活化疫苗
  • 減毒活疫苗
  • 類毒素疫苗
  • 重組疫苗
  • DNA疫苗
  • 次單位疫苗
  • 其他類型

6. 全球動物疫苗市場（依物種）

  • 伴侶動物
    • 狗
    • 貓
  • 生產動物
    • 牛
    • 豬
    • 家禽
    • 綿羊和山羊

7. 全球動物疫苗市場（按疾病）

  • 犬瘟熱
  • 狂犬病
  • 禽流感
  • 新城疫
  • 布氏桿菌症
  • 牛病毒性腹瀉（BVD）
  • 其他疾病

8. 全球動物疫苗市場（依技術）

  • 常規疫苗
  • 先進疫苗

9. 全球動物疫苗市場（依最終用戶）

  • 獸醫診所
  • 畜牧場
  • 居家醫療
  • 研究所
  • 其他最終用戶

第10章全球動物疫苗市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 合約、商業夥伴關係和合資企業
  • 企業合併與收購（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Zoetis Inc.
  • Boehringer Ingelheim GmbH
  • Merck & Co., Inc.
  • Ceva Sante Animale
  • Elanco Animal Health
  • Virbac SA
  • HIPRA
  • Phibro Animal Health Corporation
  • Vaxxinova International BV
  • Biogenesis Bago
  • Hester Biosciences Limited
  • Indian Immunologicals Ltd.
  • Neogen Corporation
  • Tianjin Ringpu Bio Technology Co., Ltd.
  • China Animal Husbandry Group
  • Jinyu Bio technology Co., Ltd.
  • Ourofino Saude Animal
  • Vetoquinol
Product Code: SMRC29953

According to Stratistics MRC, the Global Veterinary Vaccine Market is accounted for $12.98 billion in 2025 and is expected to reach $21.97 billion by 2032 growing at a CAGR of 7.8% during the forecast period. A veterinary vaccine is a biological preparation used to protect animals from specific infectious diseases by stimulating their immune systems. It contains antigens derived from pathogens such as viruses, bacteria, or parasites, which trigger an immune response without causing the disease itself. Veterinary vaccines are essential tools in preventing disease outbreaks, enhancing animal welfare, and improving food safety. They are widely used in both domestic pets and livestock to reduce the spread of zoonotic diseases, boost productivity, and decrease reliance on antibiotics in animal health management.

According to the National Bureau of Statistics China, China produced 57.94 million tonnes of pig meat in 2023, which represented a 5% increase from the previous year.

Market Dynamics:

Driver:

Rising prevalence of zoonotic diseases and livestock infections

The need for preventive measures to protect public health is growing as more diseases spread from animals to people. In order to protect animals and avoid financial losses due to disease outbreaks, livestock producers are spending money on vaccines. Vaccination programs are being promoted by governments and health organisations in an effort to curb the spread of illnesses. The need for updated and sophisticated vaccinations is further increased by the appearance of new disease strains. Innovation and growth in the veterinary vaccine sector are being driven by this increased urgency and awareness.

Restraint:

High cost and stringent regulatory approvals

Innovative vaccine development necessitates a large investment in cutting-edge technology and specialised knowledge. These costs frequently postpone product debuts and restrict access for smaller competitors. The intricacy is increased by strict regulatory approvals, which call for a great deal of safety and effectiveness testing. Time-to-market increases and innovation is discouraged by the drawn-out and expensive approval processes. All of these variables work together to limit the availability and growth of new veterinary vaccinations around the world.

Opportunity:

Advancements in vaccine technology and personalized animal care

Immune response is improved and adverse effects are decreased by innovations including vector-based vaccinations, mRNA-based vaccines, and recombinant DNA technologies. Faster reactions to newly developing zoonotic diseases are also made possible by these technologies. Demand for specialised vaccination plans based on species, breed, and health status is being driven by personalised animal care. Animal productivity and disease prevention are enhanced by this focused strategy. When taken as a whole, these dynamics greatly increase the market for veterinary vaccines' growth and relevance.

Threat:

Vaccine resistance and limited cold chain infrastructure in low-income regions

Cultural beliefs, misinformation, and doubts about the effectiveness of vaccines all play a part in this resistance. Furthermore, inadequate cold chain infrastructure compromises the effectiveness of vaccinations by affecting how they are stored and transported. The problem is made worse by inadequate refrigeration equipment and an unstable electrical supply. Disease outbreaks and vaccination coverage decline as a result of these issues. As a result, the veterinary vaccine market's expansion and efficacy in these areas continue to be limited.

Covid-19 Impact

The COVID-19 pandemic moderately impacted the Veterinary Vaccine Market. While disruptions in supply chains and reduced veterinary visits during lockdowns temporarily hindered vaccine distribution and sales, the sector rebounded as pet adoption increased and awareness of animal health grew. Governments and stakeholders emphasized disease prevention in animals to avoid zoonotic outbreaks, driving demand for vaccines. Moreover, advancements in biotechnology and diagnostic tools, inspired by the pandemic, accelerated innovation in veterinary vaccine development, supporting market recovery and long-term growth.

The recombinant vaccines segment is expected to be the largest during the forecast period

The recombinant vaccines segment is expected to account for the largest market share during the forecast period, due to safer immunization solutions. These vaccines reduce the risk of reversion to virulence, enhancing animal safety and vaccine stability. They enable rapid development against emerging diseases, supporting timely responses to outbreaks. Their efficiency in inducing strong immune responses leads to reduced dosage frequency and improved compliance. Additionally, the growing adoption of advanced biotechnology in veterinary medicine fuels the demand for recombinant vaccines globally.

The homecare settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare settings segment is predicted to witness the highest growth rate by enabling convenient and timely administration of vaccines, especially for companion animals. It reduces the need for frequent veterinary clinic visits, making preventive care more accessible and less stressful for pets and owners. Growing pet ownership and increasing awareness about animal health are driving demand for home-use vaccines and related services. Technological advancements like easy-to-use vaccine delivery systems further support at-home administration. This shift enhances vaccination compliance and boosts overall market growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing livestock populations, rising awareness of animal health, and supportive government initiatives. Countries like China, India, and Australia are witnessing increased demand for vaccines against foot-and-mouth disease, swine fever, and avian influenza. Expanding meat and dairy industries, along with improving veterinary infrastructure, further boost the market. However, challenges like regulatory barriers and limited cold chain logistics persist in rural areas.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced animal healthcare systems, strong R&D investments, and a high focus on companion animal health. The U.S. and Canada lead in innovation and vaccine adoption, with widespread use of technologies like DNA and recombinant vaccines. Stringent regulatory frameworks ensure vaccine quality but also pose entry challenges for new products. Unlike Asia Pacific, pet insurance and veterinary service access significantly influence market dynamics, reflecting the region's mature and technology-intensive approach.

Key players in the market

Some of the key players profiled in the Veterinary Vaccine Market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Ceva Sante Animale, Elanco Animal Health, Virbac S.A., HIPRA, Phibro Animal Health Corporation, Vaxxinova International B.V., Biogenesis Bago, Hester Biosciences Limited, Indian Immunologicals Ltd., Neogen Corporation, Tianjin Ringpu Bio-Technology Co., Ltd., China Animal Husbandry Group, Jinyu Bio-technology Co., Ltd., Ourofino Saude Animal and Vetoquinol.

Key Developments:

In June 2025, Boehringer Ingelheim entered a strategic collaboration with Eko Health, a leader in AI-powered detection of heart and lung diseases, to improve heart murmur detection in dogs. This partnership combines BI's expertise in canine cardiology with Eko's digital stethoscope and AI algorithms. The collaboration aims to launch a canine-specific heart murmur detection algorithm via an Eko mobile app in 2026, enhancing early diagnosis and care for canine heart disease.

In March 2025, Zoetis collaborated with the Federation of European Companion Animal Veterinary Associations (FECAVA) and the Federation of Veterinarians of Europe (FVE) to launch a handbook promoting best practices and policy recommendations to strengthen the human-animal bond. This initiative highlights Zoetis's commitment to advancing animal and human health through multi-stakeholder engagement.

In September 2024, Boehringer Ingelheim acquired Saiba Animal Health, a Swiss company specializing in therapeutic vaccines for companion animals. The acquisition brings SAH's virus-like particle vaccine platform into BI's R&D portfolio, targeting chronic diseases such as allergies, inflammation, and pain in pets. This move builds on previous collaborations between the companies and is expected to accelerate the development of innovative therapeutic vaccines with longer-lasting effects.

Types Covered:

  • Inactivated (Killed) Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • DNA Vaccines
  • Subunit Vaccines
  • Other Types

Animals Covered:

  • Companion Animals
  • Production Animals

Diseases Covered:

  • Canine Distemper
  • Rabies
  • Avian Influenza
  • Newcastle Disease
  • Brucellosis
  • Bovine Viral Diarrhea (BVD)
  • Other Diseases

Technologies Covered:

  • Conventional Vaccines
  • Advanced Vaccines

End Users Covered:

  • Veterinary Hospitals & Clinics
  • Livestock Farms
  • Homecare Settings
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Veterinary Vaccine Market, By Type

  • 5.1 Introduction
  • 5.2 Inactivated (Killed) Vaccines
  • 5.3 Live Attenuated Vaccines
  • 5.4 Toxoid Vaccines
  • 5.5 Recombinant Vaccines
  • 5.6 DNA Vaccines
  • 5.7 Subunit Vaccines
  • 5.8 Other Types

6 Global Veterinary Vaccine Market, By Animal

  • 6.1 Introduction
  • 6.2 Companion Animals
    • 6.2.1 Dogs
    • 6.2.2 Cats
  • 6.3 Production Animals
    • 6.3.1 Cattle
    • 6.3.2 Swine
    • 6.3.3 Poultry
    • 6.3.4 Sheep & Goats

7 Global Veterinary Vaccine Market, By Disease

  • 7.1 Introduction
  • 7.2 Canine Distemper
  • 7.3 Rabies
  • 7.4 Avian Influenza
  • 7.5 Newcastle Disease
  • 7.6 Brucellosis
  • 7.7 Bovine Viral Diarrhea (BVD)
  • 7.8 Other Diseases

8 Global Veterinary Vaccine Market, By Technology

  • 8.1 Introduction
  • 8.2 Conventional Vaccines
  • 8.3 Advanced Vaccines

9 Global Veterinary Vaccine Market, By End User

  • 9.1 Introduction
  • 9.2 Veterinary Hospitals & Clinics
  • 9.3 Livestock Farms
  • 9.4 Homecare Settings
  • 9.5 Research Institutes
  • 9.6 Other End Users

10 Global Veterinary Vaccine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Zoetis Inc.
  • 12.2 Boehringer Ingelheim GmbH
  • 12.3 Merck & Co., Inc.
  • 12.4 Ceva Sante Animale
  • 12.5 Elanco Animal Health
  • 12.6 Virbac S.A.
  • 12.7 HIPRA
  • 12.8 Phibro Animal Health Corporation
  • 12.9 Vaxxinova International B.V.
  • 12.10 Biogenesis Bago
  • 12.11 Hester Biosciences Limited
  • 12.12 Indian Immunologicals Ltd.
  • 12.13 Neogen Corporation
  • 12.14 Tianjin Ringpu Bio Technology Co., Ltd.
  • 12.15 China Animal Husbandry Group
  • 12.16 Jinyu Bio technology Co., Ltd.
  • 12.17 Ourofino Saude Animal
  • 12.18 Vetoquinol

List of Tables

  • Table 1 Global Veterinary Vaccine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Veterinary Vaccine Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Veterinary Vaccine Market Outlook, By Inactivated (Killed) Vaccines (2024-2032) ($MN)
  • Table 4 Global Veterinary Vaccine Market Outlook, By Live Attenuated Vaccines (2024-2032) ($MN)
  • Table 5 Global Veterinary Vaccine Market Outlook, By Toxoid Vaccines (2024-2032) ($MN)
  • Table 6 Global Veterinary Vaccine Market Outlook, By Recombinant Vaccines (2024-2032) ($MN)
  • Table 7 Global Veterinary Vaccine Market Outlook, By DNA Vaccines (2024-2032) ($MN)
  • Table 8 Global Veterinary Vaccine Market Outlook, By Subunit Vaccines (2024-2032) ($MN)
  • Table 9 Global Veterinary Vaccine Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 10 Global Veterinary Vaccine Market Outlook, By Animal (2024-2032) ($MN)
  • Table 11 Global Veterinary Vaccine Market Outlook, By Companion Animals (2024-2032) ($MN)
  • Table 12 Global Veterinary Vaccine Market Outlook, By Dogs (2024-2032) ($MN)
  • Table 13 Global Veterinary Vaccine Market Outlook, By Cats (2024-2032) ($MN)
  • Table 14 Global Veterinary Vaccine Market Outlook, By Production Animals (2024-2032) ($MN)
  • Table 15 Global Veterinary Vaccine Market Outlook, By Cattle (2024-2032) ($MN)
  • Table 16 Global Veterinary Vaccine Market Outlook, By Swine (2024-2032) ($MN)
  • Table 17 Global Veterinary Vaccine Market Outlook, By Poultry (2024-2032) ($MN)
  • Table 18 Global Veterinary Vaccine Market Outlook, By Sheep & Goats (2024-2032) ($MN)
  • Table 19 Global Veterinary Vaccine Market Outlook, By Disease (2024-2032) ($MN)
  • Table 20 Global Veterinary Vaccine Market Outlook, By Canine Distemper (2024-2032) ($MN)
  • Table 21 Global Veterinary Vaccine Market Outlook, By Rabies (2024-2032) ($MN)
  • Table 22 Global Veterinary Vaccine Market Outlook, By Avian Influenza (2024-2032) ($MN)
  • Table 23 Global Veterinary Vaccine Market Outlook, By Newcastle Disease (2024-2032) ($MN)
  • Table 24 Global Veterinary Vaccine Market Outlook, By Brucellosis (2024-2032) ($MN)
  • Table 25 Global Veterinary Vaccine Market Outlook, By Bovine Viral Diarrhea (BVD) (2024-2032) ($MN)
  • Table 26 Global Veterinary Vaccine Market Outlook, By Other Diseases (2024-2032) ($MN)
  • Table 27 Global Veterinary Vaccine Market Outlook, By Technology (2024-2032) ($MN)
  • Table 28 Global Veterinary Vaccine Market Outlook, By Conventional Vaccines (2024-2032) ($MN)
  • Table 29 Global Veterinary Vaccine Market Outlook, By Advanced Vaccines (2024-2032) ($MN)
  • Table 30 Global Veterinary Vaccine Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Veterinary Vaccine Market Outlook, By Veterinary Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Veterinary Vaccine Market Outlook, By Livestock Farms (2024-2032) ($MN)
  • Table 33 Global Veterinary Vaccine Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 34 Global Veterinary Vaccine Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 35 Global Veterinary Vaccine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.